

**Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM)
Recombinant Antibody
Catalog # APR11034****Specification**

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Product Information

| | |
|-------------------|------------------------|
| Application | FC, E, FTA |
| Primary Accession | P20273 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 146.48 KDa |

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Additional Information**Target/Specificity**

Siglec-2 / CD22

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage

-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Protein Information**Name** CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643}**Function**

Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Cellular Location

Cell membrane; Single-pass type I membrane protein


Tissue Location

B-lymphocytes.


Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Images

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) is more than 96.81%, determined by SEC-HPLC.